Monday, October 24, 2022 11:32:37 AM
$34.92 +14.34 (+69.68%)
As of Oct-24-202211:29:43 AM ET
https://stockcharts.com/h-sc/ui?s=PCVX
Update: Vaxcyte's VAX-24 Investigational Pneumococcal Conjugate Vaccine Meets Standards in Phase 1/2 Study - Shares Surge
By MT Newswires — 9:53 AM ET 10/24/22
Vaxcyte (PCVX.NaE) said Monday that VAX-24, the company's investigational 24-valent pneumococcal conjugate vaccine, met the primary safety and tolerability objectives in its phase 1/2 clinical proof-of-concept study.
The study's positive topline results mean VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2 microgram dose, which the company looks to progress into a phase 3 program.
VAX-24 showed a safety profile similar to Prevnar 20, or PCV20, for all doses studied, the company said.
Company Profile
Company LocationSan Carlos, CA
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia
Recent PCVX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:10:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:08:19 PM
- Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 08:05:00 PM
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 08:05:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 02:23:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 02:22:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 02:21:18 AM
- Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants • GlobeNewswire Inc. • 03/04/2024 01:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:02:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:00:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 09:58:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:02:21 PM
- Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/27/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:22:34 PM
- Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/15/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 10:39:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 10:37:39 PM
- Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 02/02/2024 11:39:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:07:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:06:28 PM
- Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/01/2024 09:05:49 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/31/2024 10:26:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:19:00 PM
- Vaxcyte Announces Pricing of $750 Million Public Offering • GlobeNewswire Inc. • 01/31/2024 04:37:41 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 09:13:45 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM